Allegrini A et al.
This study assessed the efficacy, safety and tolerability of a xyloglucan-based nasal spray in the treatment of symptoms of rhinosinusitis.
In this randomized, double-blind study, 40 patients with itching, nasal congestion or continuous sneezing and a Total Nasal Symptom Score (TNSS) of ≥8 were randomized to 2 weeks' treatment with a xyloglucan-based nasal spray ('xyloglucan') or a physiological saline nasal spray ('saline'). Assessments included the TNSS, rhinosinusitis severity index, nocturnal awakenings, use of rescue medication, safety and tolerability.
Baseline symptom scores were similar between groups. At treatment end, improvements from baseline were observed in both groups for TNSS (xyloglucan 58%; saline 35%, both p < 0.05) and number of nocturnal awakenings (p < 0.05). A significant improvement in the rhinosinusitis severity index was observed only with xyloglucan (p < 0.05). At treatment end, mean [SD] scores were significantly lower in the xyloglucan group versus saline group for TNSS (3.60 [2.16] vs 5.40 [2.64], p < 0.05), rhinosinusitis severity index (7.55 [1.19] vs 6.45 [1.40], p < 0.05), and for rhinorrhoea and itching (both p < 0.05). No rescue medication was used. Both treatments were well tolerated.
A xyloglucan-based nasal spray provided greater relief of rhinosinusitis symptoms than a physiological saline spray and was well tolerated.
In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.